Large cell lung cancer, also called large cell carcinoma (LCC), is one of the three main subtypes of non-small cell lung cancer (NSCLC), which accounts for about four out of every five lung cancer diagnoses. LCC makes up a relatively small share of those cases, but it stands out for its aggressive behavior and fast growth rate compared to other non-small cell types.
How Large Cell Carcinoma Is Classified
Lung cancer falls into two broad categories: small cell lung carcinoma and non-small cell lung carcinoma. Within the non-small cell group, the three major subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. LCC is defined largely by what it isn’t. When pathologists examine a tumor under the microscope and see large, undifferentiated cells that don’t fit the patterns of adenocarcinoma or squamous cell carcinoma, the diagnosis is large cell carcinoma. It’s essentially a catch-all for non-small cell tumors that lack the distinguishing features of the other subtypes.
There’s an important variant worth knowing about: large cell neuroendocrine carcinoma (LCNEC). This subtype shows specific structural patterns under the microscope and tests positive for certain protein markers tied to the neuroendocrine system. LCNEC behaves more aggressively than standard LCC and is often treated differently. Tumors that look somewhat neuroendocrine but don’t meet the full criteria fall into separate categories and aren’t classified as LCNEC.
Why It’s Considered Aggressive
Large cell carcinoma grows faster than most other non-small cell lung cancers. Researchers measure tumor growth by “volume doubling time,” which is how long it takes a tumor to double in size. For LCC, that doubling time ranges from roughly 67 to 134 days. Among all lung cancers, only small cell carcinoma matches that pace. This rapid growth means LCC can progress significantly between the time symptoms first appear and the time a diagnosis is made. In some cases, the speed of growth is so dramatic that the cancer mimics acute conditions like pneumonia, which can delay the correct diagnosis.
Symptoms and Spread
Early-stage large cell lung cancer often produces no symptoms at all. As the tumor grows, common signs include a persistent cough, chest pain, shortness of breath, unexplained weight loss, and fatigue. These overlap heavily with other lung cancers and many non-cancerous conditions, which is part of why lung cancer is frequently caught at later stages.
When LCC does spread, the most common destinations are the adrenal glands, bones, brain, liver, and the opposite lung. Metastatic symptoms depend on where the cancer lands. Bone metastases can cause deep pain and fractures. Brain metastases may lead to headaches, seizures, or dizziness. Liver involvement can produce jaundice or abdominal swelling. Spread to the other lung typically worsens shortness of breath.
How It’s Diagnosed
Diagnosing large cell carcinoma requires a tissue biopsy and careful analysis by a pathologist. The process relies heavily on immunohistochemistry, a technique that uses special stains to detect specific proteins in tumor cells. Pathologists test for markers associated with glandular differentiation (the kind seen in adenocarcinoma), squamous cell differentiation, and neuroendocrine differentiation. When a large, undifferentiated tumor tests negative for the markers that would place it in another category, it’s classified as LCC.
This testing also helps guide treatment decisions. Tumors are checked for genetic mutations in genes like EGFR and KRAS, as well as rearrangements in the ALK gene. Across all non-small cell lung cancers, roughly 33% carry EGFR mutations, about 20% have KRAS mutations, and around 3% show ALK changes. The tumor is also tested for a protein called PD-L1, which helps predict whether the cancer will respond to immunotherapy. KRAS-mutated tumors tend to have higher PD-L1 levels, while EGFR-mutated tumors tend to have lower levels.
Survival Rates by Stage
Prognosis for large cell carcinoma depends heavily on how advanced the cancer is at diagnosis. A large population-based study using national cancer registry data found that the overall one-year survival rate was 40%, the three-year rate was 21%, and the five-year rate was 15.6%. Broken down by stage, the differences are stark:
- Stage I: median survival of 42 months
- Stage II: median survival of 22 months
- Stage III: median survival of 11 months
- Stage IV: median survival of 3 months
These numbers reflect historical data and don’t fully account for newer treatments like immunotherapy and targeted therapy, which have improved outcomes for some patients in recent years.
Treatment Options
Treatment for large cell lung cancer follows the general framework for non-small cell lung cancer, with the specific approach depending on the stage and the tumor’s genetic profile.
For early-stage disease (stages I and II), surgery to remove the tumor is the primary treatment, sometimes followed by chemotherapy to reduce the chance of recurrence. Stage III cancers are typically treated with a combination of chemotherapy and radiation, and surgery may or may not be an option depending on the tumor’s location and size. Stage IV, where the cancer has spread to distant organs, is treated with systemic therapies designed to slow progression and manage symptoms.
Two newer categories of treatment have changed the landscape. Targeted therapy works by blocking specific molecular pathways that fuel tumor growth. If your tumor carries a mutation in EGFR, ALK, or certain other genes, targeted drugs can be highly effective. Immunotherapy helps your immune system recognize and attack cancer cells. It works particularly well in tumors with high PD-L1 levels, though some patients benefit even when their biomarker levels are low.
Immunotherapy for Advanced Cases
Combining chemotherapy with immunotherapy has shown promise even in difficult-to-treat cases of large cell carcinoma. In one documented case, a patient with advanced LCC and low levels of all the biomarkers that typically predict immunotherapy success (low PD-L1, low tumor mutation burden, and low immune cell infiltration) still achieved a significant partial response after receiving chemotherapy paired with an immune checkpoint inhibitor. The patient’s lymph node metastases shrank visibly on imaging after just two cycles, and the response held through five cycles before transitioning to immunotherapy alone as maintenance treatment.
This is a single case, not a clinical trial, but it reflects a broader pattern in lung cancer treatment: combining chemotherapy with immunotherapy can work in patients who might not respond well to either approach alone. For LCC patients without targetable genetic mutations, this combination is increasingly part of the treatment conversation.